IP Library Granted Patent US 8,952,169
Granted Patent B2
US 8,952,169 · App. 13/899,526 · Granted Feb 10, 2015

N-substituted benzamides and methods of use thereof

Inventors: Jean-Christophe Andrez (Burnaby, CA); Sultan Chowdhury (Burnaby, CA); Shannon Marie Decker (Burnaby, CA); Christoph Martin Dehnhardt (Burnaby, CA); Thilo Focken (Burnaby, CA); Michael Edward Grimwood (Burnaby, CA); Ivan William Hemeon (Burnaby, CA); Qi Jia (Burnaby, CA); Jun Li (South San Francisco, CA); Daniel F. Ortwine (South San Francisco, CA); Brian Safina (South San Francisco, CA); Tao Sheng (Burnaby, CA); Shaoyi Sun (Burnaby, CA); Daniel P. Sutherlin (South San Francisco, CA); Michael Scott Wilson (Burnaby, CA); Alla Yurevna Zenova (Burnaby, CA)
Assignees: Xenon Pharmaceuticals Inc.; Genentech, Inc.
C07D311/51C07D403/12C07D213/82C07D213/64C07D205/04C07D311/58C07D265/30C07D233/84C07D257/04C07C307/06C07D295/26C07D207/48C07D311/70C07D413/12C07D451/02C07D307/12C07D309/08C07D311/72C07D405/12C07D491/107C07D211/22C07D295/192C07D211/96C07D307/18C07C2101/08C07C2101/14C07C2101/18C07C2102/10C07C2102/42C07C2102/44C07C2103/74C07B2200/05C07C2101/02C07C2101/04C07C2101/16C07C2102/18C07C2102/20C07C2102/50C07C2103/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,952,169
App. No.
13/899,526
Granted
Feb 10, 2015
Kind
B2
Abstract

The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables R A , subscript n, ring A, X 2 , L, subscript m, X 1 , B, R 1 , R 2 , R 3 , R 4 , R 5 and R N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Claims (286)

1. A method of treating pain in a mammal wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein in Formula I:

R 1 is C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 alkoxy, C 3-12 cycloalkyl, C-linked C 2-11 heterocycloalkyl, heteroaryl, or —NR 1A R 1B , wherein R 1A and R 1B are each independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 alkoxy, (6-10 membered aryl)-(X R1 ) 0-1 —, (5-10 membered heteroaryl)-(X R1 ) 0-1 —, and wherein R 1A and R 1B are optionally combined to form a 3 to 9 membered heterocyclic ring optionally comprising 1 additional heteroatom selected from N, O and S and optionally fused thereto is a benzene or pyridine ring; X R1 is selected from the group consisting of C 1-4 alkylene, C 1-4 heteroalkylene, C 2-4 alkenylene and C 2-4 alkynylene; and wherein the aliphatic and aromatic portions of R 1 are optionally substituted with from 1 to 5 R R1 substituents selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, F, Cl, Br, I, —OH, —CN, —NO 2 , ═O, —(X R1 ) 0-1 NR R1a R R1b , —(X 1R ) 0-1 OR R1a , —(X 1R ) 0-1 SR R1a , —(X 1R ) 0-1 N(R R1a )C(═O)OR R1c , —(X 1R ) 0-1 OC(═O)N(R R1a )(R Rb1 ), —(X 1R ) 0-1 N(R R1a )C(═O)N(R R1a )(R R1b ), —(X 1R ) 0-1 C(═O)N(R R1a )(R R1b ), —(X 1R ) 0-1 N(R R1a )C(═O)R R1b , —(X 1R ) 0-1 C(═O)OR R1a , —(X 1R ) 0-1 OC(═O)R R1a , —(X 1R ) 0-1 —P(═O)(OR R1a )(OR R1b ),—(X 1R ) 0-1 S(O) 1-2 N(R R1a )(R R1b ),—(X 1R ) 0-1 S(O) 1-2 N(R R1a )(R R1b ),—(X 1R ) 0-1 N(R R1a )S(O) 1-2 N(R R1a )(R R1b ) and —(X 1R ) 0-1 N(R R1a )S(O) 1-2 (R R1c ), wherein X 1R is selected from the group consisting of C 1-4 alkylene, C 1-4 heteroalkylene, C 2-4 alkenylene and C 2-4 alkynylene;

wherein R R1a and R R1b are independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 cycloalkyl, phenyl, benzyl, heteroaryl, and C 2-7 heterocycloalkyl; R R1c is selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 cycloalkyl, phenyl, benzyl, heteroaryl, and C 2-7 heterocycloalkyl;

R N is hydrogen, C 1-4 alkyl or C 1-4 haloalkyl;

B is C or N;

R 2 , R 3 and R 4 are each independently selected from the group consisting of H, F, Cl, Br, I, —CN, C 1-8 alkyl, C 1-8 haloalkyl and C 1-8 alkoxy, and R 3 is absent when B is nitrogen;

R 5 is selected from the group consisting of H, F, Cl, Br, I, —CN, C 1-8 alkyl, C 2-8 alkenyl, C 1-8 haloalkyl, C 1-8 alkoxy, C 3-8 cycloalkyl, C 2-7 heterocycloalkyl, phenyl and 5-6 membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O and S, wherein said 5-6 membered heteroaryl, C 1-8 alkyl, C 3-8 cycloalkyl or C 2-7 heterocycloalkyl is further optionally substituted with from 1 to 3 R 5a substituents selected from F, Cl, Br, I, —OH, ═O, C 3-6 cycloalkyl, —CN, C 1-4 alkyl, —C 1-4 alkyl-O—C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 alkoxy;

L is a linker selected from the group consisting of C 1-4 alkylene, C 2-4 alkenylene, C 2-4 alkynylene, and C 1-4 heteroalkylene, wherein L is optionally substituted with from 1 to 3 R L substituents selected from the group consisting of ═O, —OH, —OCH 2- phenyl, C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 acyl;

the subscript m represents the integer 0 or 1;

X 1 and X 2 are each independently selected from the group consisting of absent, —O—,—S(O)—, —S(O) 2 —and —N(R X )— wherein R X is H, C 1-8 alkyl, C 1-8 acyl or —S(O) 2 (C 1-8 alkyl), and wherein if the subscript m is 0 then at least one of X 1 or X 2 is absent;

wherein ring A-(R A ) n is selected from the group consisting of

2. The method of claim 1 wherein the compound has the formula

3. The method of claim 1 wherein B is N and R 3 is absent.

4. The method of claim 1 wherein B is C.

5. The method of claim 1 wherein R 2 , R 3 and R 4 are each independently selected from H, F, or Cl.

6. The method of claim 1 wherein R 2 is H, F or Cl; R 3 and R 4 are each H; and R 5 is an optionally substituted group selected from the group consisting of H, F, Cl, Br, I, —CN, C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 cycloalkyl, and C 1-8 alkoxy.

7. The method of claim 1 wherein R 1 is C 1-8 alkyl, C 1-8 haloalkyl, C 3-10 cycloalkyl or —NR 1A R 1B .

8. The method of claim 7 , wherein R 1 is selected from the group consisting of methyl, ethyl, propyl, trifluoromethyl, difluoromethyl, monofluoromethyl, isopropyl and cyclopropyl.

9. The method of claim 1 wherein, R 1 is selected from the group consisting of:

10. The method of claim 1 wherein R 1 is selected from the group consisting of: methyl, ethyl, tert-butyl, dimethylamino, methylamino, amino, morpholino, azetidino, imidazolyl, 3-hydroxyazetidino, 3-fluoroazetidino, cyclopropyl, pyrrolidinyl, 3,3-difluoroazetidino, tert-butyl, ethyl, 2-methoxyethyl, 3-methoxyazetidino, 2-hydroxyethyl, 3-hydroxypyrrolidinyl, N-methylimidazolyl, tetrahydorofuranyl, 2-isopropoxyethyl, 3-cyanoazetidino, 2-ethoxyethyl, 2-methoxypropyl, 2-hydroxypropyl, 4-hydroxypiperidinyl, 3-methoxypyrrolidinyl and the following formulas:

11. The method of claim 1 wherein R 1 is selected from the group consisting of: methyl, ethyl, tert-butyl, dimethylamino, methylamino, amino, morpholino, azetidino, imidazolyl, 3-hydroxyazetidino, 3-fluoroazetidino, cyclopropyl, pyrrolidinyl, 3,3-difluoroazetidino, tert-butyl, ethyl, 2-methoxyethyl, 3-methoxyazetidino, 2-hydroxyethyl, 3-hydroxypyrrolidinyl, and N-methylimidazolyl.

12. The method of claim 1 wherein X 1 is —O— or —N(H)—; X 2 is absent; the subscript m is 1; and —(L)— is an optionally substituted group selected from the group consisting of C 1-4 alkylene, C 2-4 alkenylene or C 2-4 alkynylene.

13. The method of claim 1 , wherein X 1 is —O— or —N(H)—; X 2 is absent; the subscript m is 1; and —(L)— is selected from the group consisting of —CH 2 —, —C(H)(CH 3 )—, —CH 2 —CH 2 —, —CH 2 —C(H)(CH 3 )—, —C(H)(CH 3 )—C(H 2 )—, —CH 2 CH 2 CH 2 —, —CH 2 —C(H)(CH 3 )—CH 2 — or —CH 2 CH 2 CH 2 CH 2 —.

14. The method of claim 13 , wherein X 1 is —O—; the subscript m is 1 and —(L)— is —CH 2 — or —CH 2 —CH 2 —.

15. The method of claim 1 wherein X 1 is absent; X 2 is —O— or —N(H)—; the subscript m is 1; and —(L)— is selected from the group consisting of —C(H) 2 —, —C(═O)—, —C(H)(CH 3 )—, —CH 2 —CH 2 —, —CH 2 —C(H)(CH 3 )—, —C(H)(CH 3 )—C(H 2 )—, —CH 2 CH 2 CH 2 —, —CH 2 —C(H)(CH 3 )—CH 2 — and —CH 2 CH 2 CH 2 CH 2 —.

16. The method of claim 1 wherein X 1 and X 2 are absent; the subscript m is 1; and —(L)— is selected from the group consisting of —C(H) 2 —, —C(═O)—, —C(H)(CH 3 )—, —CH 2 —CH 2 —, —CH 2 —C(H)(CH 3 )—, —C(H)(CH 3 )—C(H 2 )—, —CH 2 CH 2 CH 2 —, —CH 2 —C(H)(CH 3 )—CH 2 — and —CH 2 CH 2 CH 2 CH 2 —.

17. The method of claim 1 wherein X 1 and X 2 are absent; the subscript m is 1; and —(L)— is an optionally substituted C 1-4 heteroalkylene.

18. The method of claim 1 wherein m is 0; X 1 is selected from —O—, and —N(H)—; and X 2 is absent.

19. The method of claim 1 wherein B is C; R 3 is H; R 2 is F, Cl, Br, or I; R 4 is H; and R 5 is C 3-8 cycloalkyl, wherein said C 3-8 cycloalkyl is further optionally substituted with from 1 to 3 R 5a substituents selected from F, Cl, Br, I, —OH, ═O, C 3-6 cycloalkyl, —CN, C 1-4 alkyl, —C 1-4 alkyl-O—C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 alkoxy.

20. The method of claim 19 wherein R 5 is C 3-8 cycloalkyl.

21. The method of claim 1 wherein the group:

is selected from the group consisting of

22. The method of claim 1 wherein the group:

is selected from the group consisting of

23. A method of treating pain in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound selected from:

4-((adamantan-1-ylmethoxy)-2,5- difluoro-N-(methylsulfonyl)- benzamide

4-(adamantan-1-ylmethoxy)-5- chloro-2-fluoro-N- (methylsulfonyl)benzamide

5-chloro-4-(((1S,2S,5S)-6,6- dimethylbicyclo[3.1.1]heptan-2- yl)methoxy)-2-fluoro-N- (methylsulfonyl)benzamide

4-(adamantan-2-yloxy)-5-chloro-2- fluoro-N-(methylsulfonyl)benzamide

5-chloro-2-fluoro-N- (methylsulfonyl)-4-(((1R,2R,3R,5S)- 2,6,6-trimethylbicyclo[3.1.1]heptan- 3-yl)oxy)benzamide

4-(2-(adamantan-1-yl)ethoxy)-5- chloro-2-fluoro-N- (methylsulfonyl)benzamide

5-chloro-2-fluoro-N- (methylsulfonyl)-4-(((1S,2R,4S)- 1,7,7-trimethylbicyclo[2.2.1]heptan- 2-yl)oxy)benzamide

5-chloro-2-fluoro-N- (methylsulfonyl)-4-((exo-1,7,7- trimethylbicyclo[2.2.1]heptan-2- yl)oxy)benzamide

5-chloro-2-fluoro-N- (methylsulfonyl)-4-(((1S,2S,3S,5R)- 2,6,6-trimethylbicyclo[3.1.1]heptan- 3-yl)oxy)benzamide

5-chloro-2-fluoro-4-((3- fluoroadamantan-1-yl)methoxy)-N- (methylsulfonyl)benzamide

4-(((3s,5s,7s)-adamantan-1- ylamino)methyl)-3-chloro-N- (methylsulfonyl)benzamide

4-((-adamantan-1-ylmethyl)amino)- 5-chloro-2-fluoro-N- (methylsulfonyl)benzamide

4-(adamantan-1-ylmethoxy)-3- chloro-N-(methylsulfonyl)- benzamide

4-(2-(adamantan-1-yl)ethoxy)-3- chloro-N-(methylsulfonyl)- benzamide

6-(adamantan-1-ylmethoxy)-5- chloro-N-methanesulfonylpyridine- 3-carboxamide

5-chloro-4-((-3,5-dimethyl- adamantan-1-yl)methoxy)-2-fluoro- N-(methylsulfonyl)benzamide

3-chloro-4-(((1r,3s,5R,7S)-3- hydroxyadamantan-1-yl)methoxy)- N-(methylsulfonyl)benzamide

5-chloro-2-fluoro-N- (methylsulfonyl)-4-(((1R,2S,4R)- 1,7,7-trimethylbicyclo[2.2.1]heptan- 2-yl)oxy)benzamide

4-(adamantan-1-ylmethoxy)-5- chloro-N-(N,N-dimethylsulfamoyl)- 2-fluorobenzamide

N1-((3s,5s,7s)-adamantan-1-yl)-2- chloro-5-fluoro-N4- (methylsulfonyl)terephthalamide

5-chloro-2-fluoro-4-((3- hydroxyadamantan-1-yl)methoxy)- N-(methylsulfonyl)benzamide

4-(1-(adamantan-1-yl)ethoxy)-5- chloro-2-fluoro-N- (methylsulfonyl)benzamide

4-(adamantan-2-yloxy)-5-chloro-N- (N,N-dimethylsulfamoyl)-2- fluorobenzamide

5-chloro-4-(((1S,2S,5S)-6,6- dimethylbicyclo[3.1.1]heptan-2- yl)methoxy)-N-(N,N- dimethylsulfamoyl)-2- fluorobenzamide

4-(((3s,5s,7s)-adamantan-1- yl(methyl)amino)methyl)-3-chloro- N-(methylsulfonyl)benzamide

N1-((3s,5s,7s)-adamantan-1-yl)-2- chloro-5-fluoro-N1-methyl-N4- (methylsulfonyl)terephthalamide

5-chloro-2-fluoro-4-((3- methoxyadamantan-1-yl)methoxy)- N-(methylsulfonyl)benzamide

5-chloro-2-fluoro-N- (methylsulfonyl)-4-((4- pentylbicyclo[2.2.2]octan-1- yl)methoxy)benzamide

5-chloro-4-(((1R,2s,3S,5s,7s)-5- chloroadamantan-2-yl)oxy)-2- fluoro-N-(methylsulfonyl)benzamide

5-chloro-4-(((1R,2r,3S,5s,7s)-5- chloroadamantan-2-yl)oxy)-2- fluoro-N-(methylsulfonyl)benzamide

6-(1-adamantylmethoxy)-5- cyclopropyl-N-methylsulfonyl- pyridine-3-carboxamide

4-(2-adamantyloxymethyl)-5- cyclopropyl-2-fluoro-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-5-ethyl-2- fluoro-N-methylsulfonylbenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5-ethyl-2- fluorobenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(3- hydroxyazetidin-1-yl)sulfonyl- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2- hydroxyethylsulfonyl)benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2- methoxyethylsulfonyl)benzamide

4-(1-adamantylmethoxy)-3- cyclobutyl-N-methylsulfonyl- benzamide

4-(2-adamantyloxymethyl)-5-chloro- 2-fluoro-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-3- (trifluoromethyl)benzamide

5-chloro-4-[[(1R,2R,5R)-6,6- dimethylnorpinan-2-yl]methoxy]-2- fluoro-N-methylsulfonylbenzamide

4-(2-adamantylmethoxy)-3- cyclopropyl-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-5-chloro-2- methoxy-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-3-bromo- N-methylsulfonylbenzamide

4-(1-adamantylmethoxy)-N- methylsulfonyl-3- (trifluoromethyl)benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- (methylsulfamoyl)benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluorobenzamide

4-(1-adamantylmethoxy)-5-chloro-2- fluoro-N-(2- hydroxyethylsulfonyl)benzamide

4-(1-adamantylmethoxy)-2,5- dichloro-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-5-chloro-2- fluoro-N-(methylsulfamoyl)- benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5-chloro-2- fluoro-benzamide

4-(1-adamantylmethoxy)-5-chloro-2- fluoro-N-(1-methylimidazol-4- yl)sulfonylbenzamide

4-(1-adamantylmethoxy)-5-chloro-2- fluoro-N-(2-methoxyethylsulfonyl)- benzamide

4-(1-adamantylmethoxy)-5-chloro-2- fluoro-N-(1H-imidazol-4- ylsulfonyl)benzamide

4-(1-adamantylmethoxy)-5-chloro-2- fluoro-N-morpholinosulfonyl- benzamide

5-chloro-2-fluoro-N-methylsulfonyl- 4-[[3-(5-methyltetrazol-2-yl)-1- adamantyl]methoxy]benzamide

5-chloro-N-(dimethylsulfamoyl)-2- fluoro-4-[(1-pentyl-4- bicyclo[2.2.2]octanyl)methoxy]- benzamide

5-chloro-4-[(3-chloro-1- adamantyl)methoxy]-N- (dimethylsulfamoyl)-2-fluoro- benzamide

4-(1-adamantylmethoxy)-3- cyclopropyl-N- (dimethylsulfamoyl)benzamide

4-(1-adamantyloxymethyl)-5-chloro- 2-fluoro-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-3- cyclopropyl-N-methylsulfonyl- benzamide

5-chloro-N-(dimethylsulfamoyl)-2- fluoro-4-[(3-fluoro-1- adamantyl)methoxy]benzamide

5-chloro-4-[(4,4-difluoro-1- adamantyl)methoxy]-N- (dimethylsulfamoyl)-2-fluoro- benzamide

5-chloro-2-fluoro-N-methylsulfonyl- 4-[[4-(trifluoromethyl)- cyclohexyl]methoxy]benzamide

5-chloro-4-[[(1S,2S,5S)-6,6- dimethylnorpinan-2-yl]methoxy]-2- fluoro-N-sulfamoylbenzamide

5-chloro-4-[[(1S,2R,5S)-6,6- dimethylnorpinan-2-yl]methoxy]-N- (dimethylsulfamoyl)-2-fluoro- benzamide

4-(2-adamantylmethoxy)-5-chloro- N-(dimethylsulfamoyl)-2-fluoro- benzamide

5-chloro-4-[(3-chloro-1- adamantyl)methoxy]-2-fluoro-N- methylsulfonylbenzamide

5-chloro-2-fluoro-N-methylsulfonyl- 4-[[4-(trifluoromethyl)- cyclohexyl]methoxy]benzamide

5-chloro-4-[[(1S,2R,5S)-6,6- dimethylnorpinan-2-yl]methoxy]-2- fluoro-N-methylsulfonylbenzamide

4-(1-adamantylmethoxy)-3-(2- methoxy-3-pyridyl)-N- methylsulfonylbenzamide

4-(2-adamantylmethoxy)-5-chloro-2- fluoro-N-methylsulfonylbenzamide

5-chloro-2-fluoro-N-methylsulfonyl- 4-[(1-pentyl-4-bicyclo[2.2.2]- octanyl)methoxy]benzamide

5-chloro-2-fluoro-N- methylsulfonyl-4-[(1R,2R,4S)- 1,3,3-trimethylnorbornan-2- yl]oxybenzamide

5-chloro-4-(3,3- dimethylcyclohexoxy)-2-fluoro-N- methylsulfonylbenzamide

5-chloro-N-(dimethylsulfamoyl)-2- fluoro-4-[(1S,2R,4S)-1,7,7- trimethylnorbornan-2-yl]oxy- benzamide

5-chloro-2-fluoro-N- methylsulfonyl-4-[4- (trifluoromethyl)cyclohexoxy]- benzamide

5-chloro-2-fluoro-N- methylsulfonyl-4-[4- (trifluoromethyl)cyclohexoxy]- benzamide

5-chloro-4-[(5-chloro-2- adamantyl)oxy]-N- (dimethylsulfamoyl)-2-fluoro- benzamide

5-chloro-4-[(5-chloro-2- adamantyl)oxy]-N- (dimethylsulfamoyl)-2-fluoro- benzamide

5-chloro-N-(dimethylsulfamoyl)-2- fluoro-4-[4-(trifluoromethyl)- cyclohexoxy]benzamide

5-chloro-N-(dimethylsulfamoyl)-2- fluoro-4-[4-(trifluoromethyl)- cyclohexoxy]benzamide

4-[2-(1-adamantyl)ethoxy]-5- chloro-N-(dimethylsulfamoyl)-2- fluoro-benzamide

4-(1-adamantylmethoxy)-5- chloro-N-cyclopropylsulfonyl-2- fluorobenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-[(3S)-3- hydroxypyrrolidin-1-yl]sulfonyl- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-N- cyclopropylsulfonyl-2-fluoro- benzamide

4-(1-adamantylmethoxy)-5- chloro-2-fluoro-N-[(3S)-3- hydroxypyrrolidin-1-yl]sulfonyl- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(3- fluoroazetidin-1-yl)sulfonyl- benzamide

4-(1-adamantylmethoxy)-5- chloro-2-fluoro-N-(3- fluoroazetidin-1-yl)sulfonyl- benzamide

5-chloro-4-[(4,4-difluoro-1- adamantyl)methoxy]-2-fluoro-N- methylsulfonyl-benzamide

5-cyclopropyl-4-[(4,4-difluoro-1- adamantyl)methoxy]-2-fluoro-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-pyrrolidin- 1-ylsulfonylbenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- morpholinosulfonylbenzamide

5-cyclopropyl-2-fluoro-4-[(3- fluoro-1-adamantyl)methoxy]-N- methylsulfonylbenzamide

5-cyclopropyl-2-fluoro-4-[(3- methoxy-1-adamantyl)methoxy]- N-methylsulfonylbenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-N-(3,3- difluoroazetidin-1-yl)sulfonyl-2- fluorobenzamide

2-fluoro-4-[(3-fluoro-1- adamantyl)methoxy]-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-2-fluoro- 5-methyl-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- methylbenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-N-ethylsulfonyl-2- fluorobenzamide

4-(1-adamantylmethoxy)-N-tert- butylsulfonyl-5-cyclopropyl-2- fluorobenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2- methoxyethylsulfamoyl)- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(3- hydroxypropylsulfamoyl)- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(3- methoxyazetidin-1-yl)sulfonyl- benzamide

Azetidine-1-sulfonic acid 5- cyclopropyl-4-(4,4-difluoro- adamantan-1-ylmethoxy)-2-fluoro- benzoylamide

Cyclopropanesulfonic acid 4- (bicyclo[4.1.0]hept-1-ylmethoxy)-5- cyclopropyl-2-fluorobenzoylamide

trans-2-fluoro-4-[(5-fluoro-2- adamantyl)oxy]-5-methyl-N- methylsulfonylbenzamide

cis-5-chloro-2-fluoro-4-[(5-fluoro-2- adamantyl)oxy]-N-methylsulfonyl- benzamide

6-(1-adamantylmethoxy)-5- cyclopropyl-N-(2- hydroxyethylsulfonyl)pyridine-3- carboxamide

5-chloro-2-fluoro-4-[(2-fluoro-2- adamantyl)methoxy]-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (3-hydroxyoxetan-3-yl)benzamide

6-(1-adamantylmethoxy)-5- cyclopropyl-N- (methylsulfamoyl)pyridine-3- carboxamide

4-(2-adamantyl)-3-chloro-N- (methylsulfamoyl)benzamide

4-(2-adamantyl)-3-chloro-N- methylsulfonylbenzamide

5-cyclopropyl-2-fluoro-4-[(2-fluoro- 2-adamantyl)methoxy]-N- methylsulfonylbenzamide

5-chloro-2-fluoro-N-methylsulfonyl- 4-[(3,5,7-trifluoro-2- adamantyl)methoxy]benzamide

5-chloro-N-methylsulfonyl-6- [(3,5,7-trifluoro-1- adamantyl)methoxy]pyridine-3- carboxamide

5-chloro-4-[(2-cyano-2- adamantyl)methoxy]-2-fluoro-N-(2- methoxyethylsulfonyl)benzamide

5-chloro-4-[(2-cyano-2- adamantyl)methoxy]-2-fluoro-N- (methylsulfamoyl)benzamide

5-chloro-4-[(2-cyano-2- adamantyl)methoxy]-2-fluoro-N- methylsulfonylbenzamide

4-(2-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- methylsulfonylbenzamide

4-(2-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluorobenzamide

4-(2-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2- methoxyethylsulfonyl)benzamide

4-[2-adamantyl(hydroxy)methyl]-3- chloro-N-methylsulfonylbenzamide

4-(1-adamantylmethoxy)-2-fluoro-5- iodo-N-methylsulfonylbenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-N-(2- ethoxyethylsulfonyl)-2-fluoro- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(3- methoxypropylsulfonyl)benzamide

5-cyclopropyl-2-fluoro-N- methylsulfonyl-4-[(3,5,7-trifluoro-1- adamantyl)methoxy]benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- tetrahydropyran-4-ylsulfonyl- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- tetrahydrofuran-3-ylsulfonyl- benzamide

cis-5-cyclopropyl-2-fluoro-N- methylsulfonyl-4-[[4- (trifluoromethyl)cyclohexyl]- methoxy]benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2- isopropoxyethylsulfonyl)benzamide

4-(1-adamantylmethoxy)-3,5- dichloro-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-N-(3- cyanoazetidin-1-yl)sulfonyl-5- cyclopropyl-2-fluorobenzamide

4-[(2-cyano-2-adamantyl)methoxy]- 5-cyclopropyl-2-fluoro-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (1-hydroxyethyl)benzamide

5-cyclopropyl-2-fluoro-N- methylsulfonyl-4-[[1- (trifluoromethyl)cyclohexyl]- methoxy]benzamide

trans-4-[(5-chloro-2- adamantyl)oxy]-5-cyclopropyl-2- fluoro-N-morpholinosulfonyl- benzamide

4-(1-adamantylmethoxy)-N- cyclobutylsulfonyl-5-cyclopropyl-2- fluorobenzamide

4-(1-adamantylmethoxy)-2-fluoro- N-(2- hydroxypropylsulfonyl)benzamide

4-[(2-cyano-2-adamantyl)methoxy]- 5-cyclopropyl-2-fluoro-N- (methylsulfamoyl)benzamide

5-cyclopropyl-N- cyclopropylsulfonyl-4-[(4,4- difluorocyclohexyl)methoxy]-2- fluorobenzamide

4-(1-adamantyloxymethyl)-N- (azetidin-1-ylsulfonyl)-5-chloro-2- fluorobenzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-[(3,5,7- trifluoro-1- adamantyl)methoxy]benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- iodobenzamide

N-(azetidin-1-ylsulfonyl)-5-chloro- 4-[(2-cyano-2-adamantyl)methoxy]- 2-fluoro-benzamide

N-(azetidin-1-ylsulfonyl)-4-[(2- cyano-2-adamantyl)methoxy]-5- cyclopropyl-2-fluorobenzamide

5-acetyl-4-(1-adamantylmethoxy)- N-(azetidin-1-ylsulfonyl)-2-fluoro- benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (1-hydroxy-1-methyl- ethyl)benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2-oxa-7- azaspiro[3.5]nonan-7- ylsulfonyl)benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-[[3- (hydroxymethyl)-1- adamantyl]methoxy]benzamide

5-cyclopropyl-N- cyclopropylsulfonyl-2-fluoro-4- [(3,5,7-trifluoro-1- adamantyl)methoxy]benzamide

[3-[[4-(azetidin-1- ylsulfonylcarbamoyl)-2-cyclopropyl- 5-fluoro-phenoxy]methyl]-1- adamantyl] 2,2,2-trifluoroacetate

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(2-oxa-6- azaspiro[3.3]heptan-6- ylsulfonyl)benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-4-[(3,3- dimethylcyclohexyl)methoxy]-2- fluorobenzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-[[3- (fluoromethyl)-1- adamantyl]methoxy]benzamide

5-cyclopropyl-4-[(4,4-difluoro-1- adamantyl)methoxy]-2-fluoro-N-(3- fluoroazetidin-1-yl)sulfonyl- benzamide

5-cyclopropyl-4-[(4,4-difluoro-1- adamantyl)methoxy]-2-fluoro-N-(2- methoxyethylsulfonyl)benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-4-[(4,4-difluoro-1- adamantyl)methoxy]-2-fluoro- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- tetrahydrofuran-3-ylsulfonyl- benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (1-fluoro-1-methyl-ethyl)benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N- tetrahydrofuran-3-ylsulfonyl- benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-[(3-hydroxy- 1-adamantyl)methoxy]benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-(1-oxa-6- azaspiro[3.3]heptan-6- ylsulfonyl)benzamide

5-cyclopropyl-N- cyclopropylsulfonyl-4-[(4,4- difluoro-1-adamantyl)methoxy]-2- fluorobenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (1-hydroxyethyl)benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (1-hydroxyethyl)benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-(norcaran-1- ylmethoxy)benzamide

5-cyclopropyl-N- cyclopropylsulfonyl-2-fluoro-4- (norcaran-1-ylmethoxy)benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5-cyclobutyl- 2-fluorobenzamide

4-(1-adamantylmethoxy)-5- cyclobutyl-N-cyclopropylsulfonyl-2- fluorobenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5- [cyclopropyl(hydroxy)methyl]-2- fluorobenzamide

6-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5- cyclopropyl-pyridine-3-carboxamide

6-(1-adamantylmethoxy)-5- cyclopropyl-N-(2- methoxyethylsulfonyl)pyridine-3- carboxamide

trans-N-(azetidin-1-ylsulfonyl)-4- [(5-chloro-2-adamantyl)oxy]-5- cyclopropyl-2-fluorobenzamide

5-cyclopropyl-2-fluoro-N-(2- methoxyethylsulfonyl)-4- (norcaran-1- ylmethoxy)benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-[(4- hydroxy-1- piperidyl)sulfonyl]benzamide

2-fluoro-N-methylsulfonyl-4-[[4- (trifluorornethyl)cyclohexyl]- methoxy]benzarnide

5-cyclopropyl-2-fluoro-N- methylsulfonyl-4-[[4- (trifluoromethyl)cyclohexyl]- methoxy]benzamide

single isomer

5-cyclopropyl-2-fluoro-N- methylsulfonyl-4-[4- (trifluoromethyl)cyclohexoxy]- benzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-[(3R)-3- methoxypyrrolidin-1-yl]sulfonyl- benzamide

4-(1-adamantylmethoxy)-3- chloro-2,5-difluoro-N- methylsulfonylbenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-3-chloro- 2,5-difluorobenzamide

5-cyclopropyl-2-fluoro-4-((trans- 5-fluoroadamantan-2-yl)oxy)-N- (methylsulfonyl)benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- vinylbenzamide

4-(1-adamantylmethoxy)-5- cyclopropyl-2-fluoro-N-[(3S)-3- methoxypyrrolidin-1-yl]sulfonyl- benzamide

4-(1-adamantyloxymethyl)-N- (azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluorobenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5-chloro- 2,3-difluorobenzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-3-chloro-5- fluorobenzamide

4-(1-adamantylmethoxy)-3- chloro-5-fluoro-N-methylsulfonyl- benzamide

4-(1-adamantylmethoxy)-5- chloro-2,3-difluoro-N- methylsulfonylbenzamide

4-(2-adamantyloxy)-5- cyclopropyl-N-cyclopropyl- sulfonyl-2-fluorobenzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-((trans-5- fluoroadamantan-2- yl)oxy)benzamide

5-cyclopropyl-N- (cyclopropylsulfonyl)-2-fluoro-4- ((trans-5-fluoroadamantan-2- yl)oxy)benzamide

4-(2-adamantyloxy)-N-(azetidin- 1-ylsulfonyl)-5-cyclopropyl-2- fluorobenzamide

4-(2-adamantyloxy)-5- cyclopropyl-2-fluoro-N- methylsulfonylbenzamide

5-chloro-2-fluoro-4-[(5-methoxy- 2-adamantyl)oxy]-N- methylsulfonylbenzamide

cis-4-((5-chloroadamantan-2- yl)oxy)-5-cyclopropyl-N- (cyclopropylsulfonyl)-2- fluorobenzamide

trans-4-(1-adamantylmethoxy)-2- fluoro-5-[2- (methoxymethyl)cyclopropyl]-N- methylsulfonylbenzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-4-(3,3- dimethylcyclohexoxy)-2-fluoro- benzamide

5-cyclopropyl-4-(3,3- dimethylcyclohexoxy)-2-fluoro-N- methylsulfonylbenzamide

5-cyclopropyl-N- cyclopropylsulfonyl-4-(3,3- dimethylcyclohexoxy)-2-fluoro- benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-((cis-5- fluoroadamantan-2- yl)oxy)benzamide

cis-N-(azetidin-1-ylsulfonyl)-4-((5- chloroadamantan-2-yl)oxy)-5- cyclopropyl-2-fluorobenzamide

N-(azetidin-1-ylsulfonyl)-5-chloro- 2-fluoro-4-((cis-5- methoxyadamantan-2- yl)oxy)benzamide

cis-4-((5-chloroadamantan-2- yl)oxy)-5-cyclopropyl-2-fluoro-N- (methylsulfonyl)benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-5-(2,2- difluorocyclopropyl)-2-fluoro- benzamide

4-(1-adamantylmethoxy)-N- cyclopropylsulfonyl-5-(2,2- difluorocyclopropyl)-2-fluoro- benzamide

4-(1-adamantylmethoxy)-5-(2,2- difluorocyclopropyl)-2-fluoro-N- methylsulfonylbenzamide

trans-4-((5-chloroadamantan-2- yl)oxy)-5-cyclopropyl-2-fluoro-N- ((3-fluoroazetidin-1- yl)sulfonyl)benzamide

cis-4-((5-chloroadamantan-2- yl)oxy)-5-cyclopropyl-2-fluoro-N- ((3-fluoroazetidin-1- yl)sulfonyl)benzamide

trans-4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- (2-methylcyclopropyl)benzamide

4-(1-adamantylmethoxy)-N- (azetidin-1-ylsulfonyl)-2-fluoro-5- [(E)-prop-1-enyl]benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-((trans-5- methoxyadamantan-2- yl)oxy)benzamide

N-(azetidin-1-ylsulfonyl)-5-chloro- 2-fluoro-4-((trans-5- methoxyadamantan-2- yl)oxy)benzamide

5-cyclopropyl-N- cyclopropylsulfonyl-2-fluoro-4-[[4- (trifluoromethyl)cyclohexyl]- methoxy]benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-[[4- (trifluoromethyl)cyclohexyl]- methoxy]benzamide

5-cyclopropyl-N- (cyclopropylsulfonyl)-2-fluoro-4- (((1r,4r)-4-(trifluoromethyl)- cyclohexyl)methoxy)benzamide

N-(azetidin-1-ylsulfonyl)-5- cyclopropyl-2-fluoro-4-(((1r,4r)-4- (trifluoromethyl)cyclohexyl)- methoxy)benzamide

4-(adamantan-1-ylmethoxy)-5- cyclopropyl-N-((3,3-difluoroazetidin-1- yl)sulfonyl)-2-fluorobenzamide

(1s,3R,4r,5S,7s)-methyl 4-(2-chloro-5- fluoro-4-((methy-lsulfonyl)carbamoyl)- phenoxy)adamantane-1-carboxylate

(1s,3R,4s,5S,7s)-methyl 4-(2-chloro-5- fluoro-4-((methylsulfonyl)-carbamoyl)- phenoxy)adamantane-1-carboxylate

(1s,3R,4r,5S,7s)-methyl 4-(2-chloro-5- fluoro-4-((N-methylsulfamoyl)- carbamoyl)phenoxy)adamantane-1- carboxylate

(1s,3R,4s,5S,7s)-methyl 4-(2-chloro-5- fluoro-4-((N- methylsulfamoyl)carbamoyl)- phenoxy)adamantane-1-carboxylate and

4-(adamantan-1-ylmethoxy)-5- cyclobutyl-2-fluoro-N- (methylsulfonyl)benzamide

and the pharmaceutically acceptable salts thereof.

24. The method of claim 1 wherein R 1 is selected from the group consisting of: methyl, ethyl, tert-butyl, dimethylamino, methylamino, amino, morpholino, azetidino, imidazolyl, 3-hydroxyazetidino, 3-fluoroazetidino, cyclopropyl, pyrrolidinyl, 3,3-difluoroazetidino, tert-butyl, ethyl, 2-methoxyethyl, 3-methoxyazetidino, 2-hydroxyethyl, 3-hydroxypyrrolidinyl, N-methylimidazolyl, tetrahydorofuranyl, 2-isopropoxyethyl, 3—Cyanoazetidino, 2-ethoxyethyl, 2-methoxypropyl, 2-hydroxypropyl, 4-hydroxypiperidinyl, 3-methoxypyrrolidinyl and the following formulas:

25. The method of claim 24 wherein the group:

is selected from the group consisting of

26. The method of claim 24 wherein the group:

is selected from the group consisting of

27. The method of claim 1 wherein the compound has the formula

28. The method of claim 1 wherein the compound has the formula

29. The method of claim 1 wherein the compound has the formula

30. The method of claim 1 , wherein the pain comprises neuropathic or inflammatory pain.

31. The method of claim 1 , wherein the pain comprises neuropathic pain.

32. The method of claim 1 , wherein the pain comprises inflammatory pain.

33. The method of claim 23 , wherein the compound is 4-(adamantan- 1 -ylmethoxy)-5-chloro-2-fluoro-N-(methylsulfonyl)benzamide and pharmaceutically acceptable salts thereof.

34. The method of claim 23 , wherein the compound is 4-(1-adamantylmethoxy) -3-cyclopropyl-N-methylsulfonyl-benzamide and pharmaceutically acceptable salts thereof.

35. The method of claim 23 , wherein the compound is 4-(1-adamantylmethoxy)-5-cyclopropyl-2-fluoro-N-(2-methoxyethylsulfonyl)benzamide and pharmaceutically acceptable salts thereof.

36. The method of claim 23 , wherein the compound is 4-(1-adamantylmethoxy)-5-cyclopropyl-2-fluoro-N-(3-fluoroazetidin-l-yl)sulfonyl-benzamide and pharmaceutically acceptable salts thereof.

37. The method of claim 23 , wherein the compound is 4-(1-adamantylmethoxy) -N-(azetidin- 1 -ylsulfonyl)-5—cyclopropyl-2-fluoro-benzamide and pharmaceutically acceptable salts thereof.

38. The method of claim 23 , wherein the compound is 4-(2-adamantyloxymethyl) -5—ChlorO—2-fluorO—N-methylsulfonyl-benzamide and pharmaceutically acceptable salts thereof.

39. The method of claim 23 , wherein the compound is 4-(1-adamantylmethoxy)-5-cyclopropyl-2-fluoro-N-morpholinosulfonylbenzamide and pharmaceutically acceptable salts thereof.

40. The method of claim 23 , wherein the compound is 4-(1-adamantylmethoxy)-5-cyclopropyl-N-ethylsulfonyl-2-fluoro-benzamide and pharmaceutically acceptable salts thereof.

41. The method of claim 23 , wherein the compound is cyclopropanesulfonic acid 4-(bicyclo[4.1.0]hept-1-ylmethoxy)-5-cyclopropyl-2-fluorobenzoylamide and pharmaceutically acceptable salts thereof.

42. The method of claim 1 , wherein the pain is acute pain.

43. The method of claim 1 , wherein the pain is chronic pain.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: LI, JUN; ORTWINE, DANIEL F.; SAFINA, BRIAN; SUTHERLIN, DANIEL P.
To: GENENTECH, INC.
Reel/Frame 033228/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: CHOWDHURY, SULTAN; DEHNHARDT, CHRISTOPH MARTIN; FOCKEN, THILO; GRIMWOOD, MICHAEL EDWARD; HEMEON, IVAN WILLIAM; JIA, QI; SUN, SHAOYI; ZENOVA, ALLA YUREVNA
To: XENON PHARMACEUTICALS INC.
Reel/Frame 033228/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: ANDREZ, JEAN-CHRISTOPHE; DECKER, SHANNON MARIE; SHENG, TAO; WILSON, MICHAEL SCOTT
To: XENON PHARMACEUTICALS INC.
Reel/Frame 033228/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2013
From: LI, JUN; ORTWINE, DANIEL F.; SAFINA, BRIAN; SUTHERLIN, DANIEL P.
To: GENENTECH, INC.
Reel/Frame 031482/0099 →
Priority Claims (1)
WO PCT/IB2012/001324 · May 22, 2012 · international
Continuity (3)
Provisional Application 61650934 · May 23, 2012
Provisional Application 61785601 · Mar 14, 2013
Related Publication 20130317001A1 · Nov 28, 2013